Press Releases

STOCKHOLM, Aug. 8, 2019 /PRNewswire/ -- The data generated from a unique single sequence on the Siemens Healthineers MRI system and SyMRI software provide quantitative MRI, tissue specific parametric maps (R1, T1, R2, T2 and PD), multiple contrast-weighted images and tissue volumes. This supports a faster scan time while providing more information

LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that the FDA has accepted the company's IND filing for AGEN2373, a milestone&nbs

LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided corporate updates and reported financial results for the second quarter of 2019.

Record Revenue of $9.4 Million and Adjusted EBITDA of $5.1 Million LAVAL, QC, Aug. 8, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with manufacturing capabilities and a portfolio

BETHESDA, Md., Aug. 8, 2019 /PRNewswire/ -- The American College of Medical Genetics and Genomics (ACMG) is announcing the establishment of an Evidence-Based Guidelines (EBG) Program, including a staff team dedicated to new evidence-based guideline development in the medical genetics and genomics field.

- Sierra preparing to launch the MOMENTUM Phase 3 myelofibrosis clinical trial expected in Q4 2019 -- Exploring non-dilutive options to support future continued development of DDR portfolio - VANCOUVER, Aug 8, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics

BURLINGTON, ON and BRANTFORD, ON, Aug. 8, 2019 /PRNewswire/ - Rapid Dose Therapeutics Corp. (CSE: DOSE), ("RDT")

VANCOUVER, Aug. 8, 2019 /PRNewswire/ - Choom™ (CSE: CHOO; OTCQB: CHOOF), is pleased to announce that an Alberta provincially approved cannabis retail licensee ("Licensee") is opening a cannabis retail store in Medicine Hat, Alberta operating under the Choom brand.

OLDWICK, N.J., Aug. 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has dosed the first patients in its PREVAIL (PRV-3279 EVAluation In Lupus) study, a Phase 1b/2a clinical trial evaluating P

BERLIN and CAMBRIDGE, Mass., Aug. 8, 2019 /PRNewswire/ -- Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary i